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Many autoimmune diseases, including multiple sclerosis (MS), rheumatoid arthritis (RA), and 
celiac disease (CD), arise from improper immune system recognition of self or benign peptides as 
threats. No autoimmune disease currently has a cure. Many treatments suppress the entire immune 
system to decrease symptom severity. The core molecular interaction underlying these diseases 
involves specific alleles of the human leukocyte antigen (HLA) receptor hosting the 
immunodominant peptides associated with the disease (i.e. myelin basic protein, Type II collagen, 
or α-gliadin) in their binding groove. Once bound, circulating T-cells can recognize the HLA-
antigen complex and initiate the complex cascade that forms an adaptive immune response. This 
initial HLA-antigen interaction is a promising target for therapeutic intervention. Two general 
strategies have been pursued: altered peptide ligands (APLs) that attempt to recruit a different class 
of T-cell to induce an anti-inflammatory response to balance the pro-inflammatory response 
associated with the antigen; and HLA blockers (HLABs), peptides that, due to a much higher 
affinity for the HLA receptor, quantitatively displace the antigen, inhibiting the immune response. 
Both approaches would benefit from improved HLA-drug binding, but as the HLA receptors are 
highly promiscuous, the binding sites are not specific for any natural amino acid. Unnatural amino 
acids, either designed or screened through high-throughput assays, may provide a solution. This 
review summarizes the nascent field of using non-canonical residues to treat MS, RA and CD, 
focusing on the importance of specific molecular interactions, and provides some examples of the 





The increasing understanding of the critical role of peptides in human biology has led to a 
renewed focus on developing peptide therapeutics. Drug discovery and design has long been 
centered on small molecule synthesis.1 However, small molecules lack the  precise specificity of 
peptides2 and very often have off-target effects due to undesired secondary interactions. The 
comparatively large size and specificity of peptides offers a promising alternative. However, 
despite this potential, peptides have only seen very limited use as therapeutics partially due to 
cellular-uptake concerns, partially due to their low biostability, and partially due to their 
comparative synthetic complexity and/or expense.3 However, one of the greatest limiting factors 
is the co-evolution challenge. Therapeutic peptides are best suited for inhibiting, blocking, or 
agonizing targets that have endogenous peptide ligands with which they have co-evolved over 
approximately the past four billion years. Many of the natural targets have exceptional affinity, 
and so displacing them is a significant challenge. However, the systems have been developed 
exclusively using, with a few very notable exceptions, the canonical 20 amino acids. Using 
unnatural amino acids can possibly decouple this problem by introducing residues that can take 
advantage of latent interactions unavailable to any natural residue. With recent advances in in silico 
peptide design, and access to the significant computational resources required for this type of 
research;4 synthetic chemistry to develop new methods to access unnatural amino acids in efficient, 
rapid, and general ways;5 the understanding of peptide architectures, sequences, and modifications 
to improve proteolytic stability; 6 and solid-phase peptide synthesis to allow for faster, cleaner, 
and massively parallel syntheses,7 we are potentially already in a renaissance for peptide-based 
drugs.  
 One of the most promising applications of the new peptide science is for developing new 
therapeutics for autoimmune disorders, especially the major histocompatibility complex (MHC) 
Type II disorders.8 These are all conditions where an individual carries a certain allele of the 
receptor that is capable of improperly identifying a self-peptide as foreign. This initiates an 
immune response whose symptoms differ based on the target protein or organ. Thus, the peptides 
that cause disease are not the natural ligands of the receptor. This makes them very promising 
targets for the therapeutic intervention with synthetic peptides that interfere with the immunogenic 
interaction.  MHC Type II diseases include many of the most common immune diseases: multiple 
sclerosis (MS), celiac disease (CD), rheumatoid arthritis (RA) and type 1 diabetes (T1D) among 
many others.9 The presence of the allele significantly increases susceptibility to develop the 
disease but is not sufficient for disease onset.10 The overall mechanism in these types of disorders 
is very similar. 
MHC class II molecules, also known as human leukocyte antigen (HLA) receptors, are 
present on the surfaces of epithelial cells.11  They are comprised of a heterodimer of two proteins: 
the α and β chains. The peptide antigen binding groove emerges from the organization of two α 
helices forming walls, supported by an eight strand β-pleated sheet floor which open on both ends 
(Figure 1A).12 These receptors present antigenic peptides to CD4+ T cells initiating an immune 
response resulting in disease symptoms. The binding groove and antigenic peptide conformation 
is highly conserved between MHC type II molecules. The antigenic peptide is bound in an 
extended conformation within the groove and is held in position through non-covalent interactions 
between the peptide backbone and sidechains and the surface residues on the receptor.12  Generally, 
nine amino acids form the core binding region however the peptide may be longer as the binding 
pocket is open on both sides. In the bound conformation, several of the amino acid side-chains 
face towards the groove into distinct pockets. These residues form additional attractive interactions 
stabilizing the peptide-MHC complex and are termed anchor residues, found in positions p1, p4, 
p6 and p9 (Figure 1B). However, this pattern can vary based on the disease and associated peptide. 
For example, in some cases, it is p7 instead of p6 which is the anchor residue. The nature of the 
pockets (size, shape, hydrophobicity, electrostatic and electronics), as well as the preferred amino 
acid residue, varies depending on the exact sequence of the HLA receptor. These factors determine 
which peptides it is capable of recognizing, and defines which residues on the peptide epitope are 
involved in binding to the HLA. Several of the epitope’s other amino acids in this core HLA-
binding sequence of nine amino acids point away from the binding groove and participate in T cell 
recognition (Figure 1C). The T-cell uses its receptor then binds from the top face and forms a 
MHC-peptide-T cell ternary complex. This interaction then initiates the complicated adaptive 
immune response. Although incredibly highly polymorphic across the population, individuals have 
only between 8 and 12 different MHC receptors. However, there are approximately 108-1012 
different circulating T-cell receptors at any one time, and the best estimates indicate that the genetic 
code encodes on the order of 1020 possible different T-cell receptors.13 This difference in 
polymorphism is key to the interest that these materials have drawn from researchers using 
unnatural amino acids: the MHC receptors need to be capable of binding a very wide variety of 
different peptides; they are the primary recognition element for identifying pathogens for the 
immune system. However, because they must be promiscuous binders, they are not particularly 
strong binders of any given antigen; furthermore, as the pockets and potential interaction points 
along their surface must be capable of accepting a number of different amino acid guests, they are 
not specific for any given amino acid. As peptides are the natural ligand responsible for disease 
initiation, treatment with peptide drugs has been a focus of autoimmune research. There are two 
potential mechanisms that can be envisaged. The Altered Peptide Ligands (APLs) attempt to 
modulate the T-cell receptor face of the peptide in order to change the T-cell response from a pro-
inflammatory mechanism to an anti-inflammatory mechanism.14 HLA-blockers (HLAB) on the 
other hand seek to improve binding to the MHC, and thereby competitively displace the antigenic 
peptide and consequently prevent T-cell recognition of the complex altogether.15 APLs do not need 
to displace all the antigens to function: they need to occupy sufficient MHC receptors that their 
anti-inflammatory response balances the pro-inflammatory response elicited from the antigen. 
However, no traditional APL has reached the clinic (although there are a number of candidates, 
such as glatiramer triacetate16 that may have some APL activity in addition to other mechanisms). 
HLABs on the other hand rely on near complete displacement of the natural antigen. By removing 
the antigen, you remove the downstream immune response; but, for this to be viable, displacement 
must be near complete, and this implies an exceptional preference of the HLAB over the antigen 
for the HLA receptor. However, as the receptor is promiscuous by design, this is very difficult to 
do with natural amino acids. The current best efforts are on the order of a 55-fold improvement as 
observed by Sollid and co-workers in a CD model.17 But that does not mean that an unnatural 
amino acid cannot be designed that is specific for the pocket. These residues could, in theory, show 
far higher specific affinity, providing the required orders of magnitude increase in affinity that 
could lead to a new class of specific treatments for autoimmune diseases. To do this rationally, a 
detailed understanding and modelling of the various potential interactions that can be exploited to 
improve affinity is required. 
 
Figure 1. Overview of the MHC-peptide interaction. A) Top-down view of a crystal structure of 
an MHC-Type II receptor associated with RA18; B) Cartoon representation of myelin basic peptide 
87-99, the immunodominant epitope strongly associated with the development of MS bound to 
HLA-DR2, an HLA receptor associated with many cases of MS. Key HLA contact residues are 
highlighted in green, key TCR-contact residues in red. The pockets on the HLA are indicated and 
their representation is broadly proportional to their respective size. C) Image of a T-cell receptor 
(top, yellow coil and pink surface) interacting with the HLA (bottom, grey surface)-antigen 
(middle yellow surface) complex obtained from an MS related crystal structure.19  
 
Consideration of the nature and strength of each interaction between the amino acids of the 
antigen and the receptor, along with both any emergent negative/positive cooperative role in 
binding affinity, and any potential entropic concerns, is essential for the successful development 
of unnatural amino acids for treatment. High binding affinities are required to outcompete the 
natural antigenic peptide, and incorporating residues which contain stabilizing non-covalent 
interactions (i.e., H-bonding, π···π, and X−H···π interactions) are essential, but many of the 
binding events are emergent phenomena arising from co-operativity effects including a number of 
adjacent residues on both receptor and peptide. Consequently, an in-depth knowledge of the 
receptor pockets (i.e. their size, shape, and charge distribution) is absolutely necessary for the 
rational design of new unnatural amino acids. Many studies have attempted to improve binding 
affinity by substituting these anchor residues for other amino acids (single mutations, double 
mutations, alanine scans, randomized libraries, etc), but they have primarily focused on natural 
amino acids and few have utilized unnatural amino acids.20  
Another key aspect in a successful therapy is modulation of T-cell activation. A high-
affinity HLAB may simply elicit an increased immune response, and it is essential to prevent this. 
This is where the HLABs and APLs differ: the APLs, through the modification of residues 
interacting with the T-cell, seek to modulate the immune response and recruit anti-inflammatory 
Th2 cells rather than pro-inflammatory Th1. HLABs seek to modify the T-cell face to prevent T-
cell interaction at all. To achieve this goal, strategies including the incorporation of blocking 
residues, cyclizations, and crosslinking agents have been explored.  
Central to all of this work is the use of new unnatural amino acids, and there are isolated 
examples employed for the different MHC Type II conditions. The purpose of this current review, 
organized by disease state rather than amino acid structure, is to consider the efforts to date using 
unnatural amino acids for the treatment of MHC Type II disorders as a whole rather than as isolated 
examples. The variety of methods used for creating these residues, and the challenges of 




Celiac disease is characterized by a lifelong sensitivity to gluten proteins found in wheat, 
barley and rye known as gliadins, hordeins and secalins respectively. It affects approximately 1% 
of the western population and the number of those affected is expected to increase.21 Ingestion of 
gluten causes an immune response that damages the intestinal tract resulting in chronic diarrhea, 
malabsorption (causing anemia and vitamin/mineral deficiencies), and a host of related 
complications. Currently the only treatment option available is a gluten free diet, which can be 
difficult to maintain.22  
  
 
Figure 2. Energy minimized molecular models derived from the crystal structures23 of the pockets 
of interest; the surface represents the HLA (HLA-DQ2), while the α-gliadin, LQPFPQPQLPY, is 
represented by the green peptide. A) Overall view of the binding groove with the prolines of the 
antigen highlighted in yellow. B) Expanded view of the P1 pocket. The mutated Pheα53 residue 
is highlighted in black. In other members of this class it is an arginine, and it extends through the 
P1 pocket (outlined in pink), blocking it. C) Expanded view of the P4 (pink outline) and P6 (green 
outline) pockets. The Lysβ71 residue that separates the two pockets is highlighted in black, while 
the two glutamine residues that occupy (in the case of p6, poorly) are highlighted in yellow. D) 
Expanded view of the large, empty, p9 pocket (outlined in pink) partially occupied by tyrosine. 
 
The majority (>90%) of patients express allele HLA-DQ2, while a small portion are 
carriers for HLA-DQ8 (5%). The epitope recognition preferences of these two receptors have been 
thoroughly studied and are well understood and crystal structures of the receptor bound to gliadin 
have been isolated. Gluten peptides are rich in proline and glutamine residues. High proline content 
also results in increased peptidase resistance allowing them to avoid degradation and reach the 
intestinal tract. Gluten peptides are then recognized by tissue transglutaminase (TTG) which is 
capable of deamidating gluten peptides resulting in gliadins which have increased affinity to the 
HLA receptor (due to their negative charge) and increased T cell response.24 It is however, possible 
in certain cases for HLA-DQ2 to recognize natural gluten peptides, though they are more often 
recognized in their deamidated form as gliadins.25 TTG has been shown to participate in wound 
healing and apoptosis. It is no surprise then that it is upregulated in inflamed intestinal tissues. It 
has been proposed that a viral infection or other environmental factors causing inflammation 
trigger TTG. This leads to deamidation of the gliadins present in any wheat-rich diet and onset of 
CD.26 α-Gliadin, both the 17mer and 33mer, containing the sequence LQPFPQPQLPY, is the 
immunodominant peptides (Crystal structure, 1S9V; Figure 2),23, 27 though many other HLA-DQ2-
binding peptides are also capable of triggering an immune response.28 The 33mer peptide is 
particularly immunogenic due to high protease resistance and the presence of six overlapping 
binding epitopes. Trying to target the antigen is challenging as there are many potential antigens. 
Trying to interfere with the downstream immune response, i.e. using NSAIDs or corticosteroids, 
is the acute treatment but is only partially effective and leads to a general depression of the immune 
system, increasing susceptibility to infection. New therapeutic approaches are required and APLs 
and HLABs have shown promise. Many of these have used unnatural amino acids to improve 
affinity or prevent T-cell recognition.  
Whenever unnatural amino acids are to be used, it is essential to have an understanding of 
the fundamental interactions of the natural antigen. For the purposes of this review, we will provide 
a more detailed analysis of the DQ2 receptor to illustrate the point.23 For other diseases, we will 
direct the reader towards the initial crystal structure and computational reports. The HLA-DQ2 
receptor has a large pocket at p1. Due to a mutation Argα53, normally conserved in other DQ 
molecules and forms hydrogen bonds as a key anchor residue, is missing in the p1 pocket. Its 
absence makes the pocket far larger, and allows for the incorporation of a proline in the p1 
position.27 Proline residues can also be incorporated at p3, p5, p8 and p9. Glutamic acid, the result 
of TTG activity, is preferred in positions 4 and 6 as negatively charged residues form favourable 
interactions in these positions (Figure 2). A mutation results in the replacement of the blocked 
Tyr30β normally found in the DQ p6 pocket with serine, resulting in a pocket capable of hydrogen 
bonding. Nearby Lysβ71 results in preference for negative charges and nearby Tyr9β also 
participates in hydrogen bonding; this complex is perfect for a negatively charged residue such as 
Glu.23 Argβ70, Asnα62 and Asnα11 were found to form important interactions in p4. It was also 
noted that the formation of attractive van der Waals interactions are important for interactions 
using p1, p4, and p7; while the residue at p9 was less important in the natural antigen as the pocket 
is so large that occupying residues do not form strong interactions with the receptor. Prolines at 
positions 5 and 8 face away from the HLA, making them suitable for modifications that affect T 
cell recognition (Figure 2).29 
 
  
Figure 3. Unnatural amino acids utilized in the development of APLs and HLABs for CD. 
 
In one study, hydroxyproline or dihydroxyproline  (1, 2; Figure 1) residues were introduced 
into the α-gliadin peptide to reduce the binding affinity of gluten.29 The aim was to develop a low 
affinity peptide which could then be genetically incorporated into wheat. These modifications can 
be achieved both enzymatically and chemically. The hydroxyproline peptides were studied 
computationally and it was found that substituting the prolines at positions 5 and 8 slightly 
improved binding as they formed better interactions with water. Expanding on this work, 
Kapoerchan and coworkers used azidoproline to suppress T cell responses.30 (4S)-4-azido-L-
proline (3) or (4R)-4-azido-L-proline (4) were introduced at p3 and p5.31 To further improve their 
T-cell blocking activity, they could be readily functionalized post-peptide synthesis using copper-
assisted azide-alkyne cycloaddition (CuAAAC) chemistry. These azides can be functionalized 
with various functional groups such as N-methylacrylamide or N-acryl-L-phenylalanine methyl 
ester resulting in amino acids 5-8. Most modified peptides had approximately the same binding 
affinity to HLA-DQ2 as the unmodified version however, one case resulted in drastically reduced 
binding, which was potentially due to the presence of steric clash between the peptide and HLA 
receptor. These modified peptides showed reduced T cell stimulation with larger substituents 
showing the lowest T cell stimulation. This illustrates that blocking T-cell recognition is a 
potentially viable approach in the prevention T-cell stimulation. However, when studied in a 
competition assay, the peptides did not have sufficiently high binding affinity to outcompete 
gliadin and prevent T cell activation.  
To address this issue, the same team undertook another study to create a high affinity 
gliadin analog.32 In this study they took the peptide FVAEYEPVL which was predicted to be a 
strong HLA binder and tested N-terminal extensions and single amino acid substitutions. Their 
results showed the ADA extension increased binding affinity 5-6 fold while the best binder after 
amino acid substitution was found to be ADAYDYESEELFAA. They then used unnatural amino 
acids at p1. The p1 pocket is large and hydrophobic, and as mentioned above, natural amino acids 
are incapable of completely filling this pocket. Eight unnatural amino acids (structure 9-16; Figure 
3) were designed, synthesized, and incorporated into the P1 position in place of the tyrosine. Many 
of these molecules had been previously prepared, but several of the syntheses are noteworthy. 
The fluorescent derived amino acid Nα-Fmoc-Nβ-(6-N,N’-dimethyl-aminonaphtalimidoyl)-
L-diamino-propionic acid (6-DMNA) (9) was selected as its increased bulk could provide a good 
fit and consequently improve binding. This amino acid was synthesized using 3-nitrobenzaldehyde 
(17; Scheme 1) as the starting material. Protection of the aldehyde 18 was followed by nucleophilic 
substitution with chloromethyl phenyl sulfone to provide 19. Deprotection, and addition of diethyl 
maleate allowed for the in situ cyclization and elimination of the phenylsulfone provides the diester 
20. Reductive amination of the nitro group to the amine 21, followed by saponification of the ester 
functionality to allow for anhydride formation provides electrophile 22. The anhydride was then 
treated with the diaminopropanoic acid derivative 23 (derived from serine)33 to provide maleimide 
24. Finally, removal of the allyl ester provides the Fmoc-protected amino acid 25, the protected 
derivative of 9, which is suitable for solid-phase synthesis. 
 
 
Scheme 1. Synthetic procedures for the synthesis of fluorescent Fmoc 25, the protected analogue 
of amino acid 9.  
 
 
Lysine is a large residue, and consequently acts as an excellent platform for elaboration for 
filling the p1 pocket. To prevent the repulsion of a positively charged side chain amino acid with 
the charged His side chain located on the wall of the pocket, a neutral hydroxyl analogue (10 in 
Figure 3) was designed (Scheme 2). Oxidation of the primary alcohol of protected L- homoserine 
26 provided aldehyde 27. Wittig olefination with hydroxylated reagent 28, resulted in the 
formation of aldehyde 29. Subsequent 1,2 reduction and concomitant transesterification generated 
ethyl ester 30. Saponification of the ester provided the de-protected Boc-building block 31. 
Replacing the Boc group with an Fmoc group for the required SPPS strategy completes the 
synthesis of 10a.  
 
Scheme 2. Synthesis of the Fmoc derivative, 10a, of hydroxylated lysine analogue 10. 
 
In general, using bulkier, and/or charged residues takes advantage of the formation of 
stabilizing interactions that are unavailable to the natural residues and was found to increase 
binding affinity by factors of 4-5. The incorporation of unnatural amino acids is a promising 
approach for increasing the binding affinity of peptides. However further increases in binding 
affinity require careful design as the gains using this trial-and-error approach are modest.  
Another study by Siegel and coworkers modified the α1-gliadin peptide to incorporate 
aldehyde bearing amino acid derivatives (32-36; Figure 3) in the p4 and p6 positions.34 These 
aldehyde derivatives are capable of reversibly condensing with Lysβ71 located near the p4 and p6 
positions to form an imine. They found when the appropriate length aldehyde 33 was employed, 
binding affinity to the DQ2 increases and the dissociation half-life increases by a factor of eight 
compared to the unmodified peptide. As expected, either mono-aldehyde peptide also had a much 
higher degree of T-cell activation due to their more stable occupation of the HLA receptor. The 
dialdehyde substituted peptide, however, decreased T-cell stimulation, which was proposed to be 
a result of the structural changes induced on the T-cell binding face due to the mutated residues. 
Exploiting this behavior, they then modified the peptide to act as a HLAB based on their previously 
reported work.35 This involved replacing two solvent-exposed leucine residues with succinyl-
functionalized lysine moieties 38. This new peptide, however, was less effective at preventing T-
cell activation despite the incorporation of imine-forming residues (ketones and aldehydes 32-38). 
It would be interesting to investigate the biological behaviour of the potent DQ2-binding mono-
aldehyde peptides functionalized with the blocking residues. The longer half-life and increased 
binding affinity would potentially assist the peptide to outcompete gliadin and prevent T cell 
proliferation. 
The aldehydes (33-36) used in this report were synthesized starting from an Fmoc protected 
lysine homologue incorporated in a peptide chain using Boc SPPS (39; Scheme 3). The Fmoc 
protecting group was cleaved using 20% piperidine to yield free amine 40. This side chain nitrogen 
was capped by coupling an Fmoc protected serine residue to the free amine using HBTU to 
generate 41. SPPS can then be continued. Following cleavage from the resin support, the Fmoc 
protecting group was removed (43) and then the peptide was treated with sodium periodate at pH 
7 in a phosphate solution to produce glyoxamide 44.  
 
 
Scheme 3. Synthesis of glyoxamide-functionalized amino acid 44 from diamino ethanoic acid-
derived residue 39.34 R and R1 represent peptide chains or hydrogen if the residue is at the end of 
the chain. 
 
In two HLAB studies conducted by Xia and coworkers, three different T-cell inhibitory 
mechanisms were investigated.35-36 The first incorporated the same bulky blocking groups in the 
p5 and p7 positions: lysine residues modified with succinyl moieties (38).35 A dimeric version of 
the unmodified peptide was then synthesized by cross-linking lysine residues in p7 using a 
hexaethylene glycol linker. The binding of the succinyl peptides was comparable to the unmodified 
peptide, but the dimeric peptide had higher affinity. The dimeric peptides form complexes with 
two DQ2 molecules simultaneously; but, this is only observed at pH 5.5.  Neither the blocking nor 
the dimeric peptides elicited a T cell response, and were both even found to be able to 
competitively inhibit T-cell proliferation in the presence of antigenic peptides in a dose dependent 
manner.  
The second study focused on the synthesis of these dimeric and cyclic peptides.36 Dimeric 
peptides which were synthesized using thiol-maleimide bonds were unable to prevent T cell 
proliferation. Two types of cyclic peptides were then tested, one in which the core peptide is 
flanked by a glycine spacer and then linked via disulfide bond or ones in which there is an internal 
cyclization using internal lysine residues and polyethylene glycol linkers. These peptides had 
similar or slightly better binding than the reference peptide. The disulfide peptides again did not 
inhibit T cell activation while two of the PEG based peptides which used a longer gliadin epitope 
did effectively inhibit T cell proliferation. The discrepancy is potentially due to the in situ reduction 
of the disulfide bond, cleaving the cycle. Although the binding was deemed insufficiently potent 
to act as a true HLAB, it is an excellent proof-of-concept. Combining both dimerization and 
cyclization along with increasing peptide-MHC affinity through modifications of anchor residues 
may provide an effective therapeutic approach for celiac disease and other MHC type II conditions 




Rheumatoid arthritis is the chronic inflammation of the joints caused by an autoimmune 
response to the synovium (lining of the joints) which eventually leads to cartilage destruction, bone 
erosion, and loss of joint function.37 While it is most commonly associated with joint damage, RA 
can also cause complications of the skin, eyes, lungs and heart among other organs and structures. 
41 of every 100,000 people will be diagnosed with RA. There is no cure and current treatments 
focus on reducing inflammation and preventing disease progression and subsequent join damage. 
Many of the drugs that are used to slow progression of the disease modulate various components 
of immune system activation or inflammation pathway which results in side effects such as an 
increased risk of infection.38 
The main genetic factors associated with RA are the HLA receptors HLA-DR1 and HLA-
DR4. The disease etiology is unknown although several potential antigens including proteoglycan, 
gp39 and type II collagen have been associated with disease onset. Collagen-induced arthritis is 
the most widely used model in the study of RA. The CII250-270 sequence is highly immunogenic, 
and CII263-272 is currently believed to be the immunodominant peptide and is recognized by both 
HLA-DR4 and DR1 molecules.39 Residues p1 263F and p2 264K were found to be key anchor 
residues for HLA-DR binding while residues p5 267Q and p9 270K are the key TCR contact 
residues (Figure 4).40 
 
   
 
Figure 4. Crystal structures39a of the pockets of interest (energetically minimized); the surface 
represents the HLA-DR4, while the CII263–272 peptide is represented by the green peptide. A) 
Overall view of the receptor with the key anchoring residues highlighted in yellow. B) Expanded 
view of the P1 pocket showing the incomplete fit of a flat Phe. C) View of the P4-6 region 
highlighting the importance of backbone-receptor hydrogen bonds to orient the system. D) 
Highlight of the P9 pocket showing the incomplete filling of the electropositive surface by the 
proline residue. 
 
Modifications using natural amino acids have been extensively studied and have shown 
promise in inhibiting T cell activation. This has been most successfully used to substitute the TCR 
contact residues to generate APLs that modulate the response into an anti-inflammatory mode.41 
One early study into the use of APLs focused on editing the epitope of the CII245-270 peptide to 
develop a competitive binder.42 This peptide is a major T cell determinant in I-Aq mice. Key 
residues required for T-cell stimulation were substituted with others based on the type I collagen 
epitope (245-270) which naturally contains hydroxyproline residues. One promising peptide (I260, 
A261, and F263 to A260, hydroxyproline261 and N263) reduced T-cell stimulation and decreased 
cytokine production, even when tested in a competition assay with the immunogenic CII245-270. 
This observation indicates that it is able to competitively bind to the HLA, and that the mutations 
likely affect TCR contact mode as expected.  
In a study by Falcioni and coworkers, unnatural amino acids (45-73; Figure 5) were 
substituted for both MHC anchor residues as well as TCR contact residues based on computational 
modeling to generate heptapeptides.43  
 
 
Figure 5. Unnatural amino acids used in the development of APLs for RA. 
 
The aim was to create HLABs: improve HLA binding, inhibit TCR recognition and 
increase peptide stability. Anchor position p1 was found to have a preference for large cyclic 
residues (Tyr, Phe, Trp) in the case of DR1 and several DR4 alleles which preferred simpler 
aliphatic chains (Ile, Leu, Val). To make a general candidate, cyclohexyl alanine (45; Figure 5) 
was incorporated in this position along with the slightly larger residues (46-48). The canonical 
residues Met, Ser, and Leu were found to be optimal for p4, p6, and p7 respectively. The research 
team also probed the importance of backbone hydrogen bond formation using N-methylated 
derivatives of the amino acids. Hydrogen bonds formed by the amide bonds of the residue at 
position p2 and p4 were found to be essential for peptide binding, and loss of these H-bonds 
resulted in a several hundred-fold decrease in affinity. In contrast, N-methylation at either p3 or 
p5 had little to no effect on binding affinity but greatly increased resistance to protease degradation. 
None of the unnatural amino acids (49-51) examined at p2 improved the binding affinity compared 
to Arg: the backbone hydrogen bond is critical for binding and changes in the backbone structure 
are not tolerated. There is a small hydrophobic pocket near p3 which the authors attempted to 
exploit using residues 52-59. These compounds increased binding affinity of the peptide. Due to 
the importance of the p4 hydrogen bond, this position was sensitive to substitution, and only 45 
and 60 were useful; for p7, residue 62 was found to provide a useful increase to binding affinity. 
There is significant diversity in this library, and the synthesis of these amino acids can prove 
instructional. 
Unnatural amino acids are often considered a recent area of exploration, but the field 
stretches back to the beginning of modern synthesis. t-Butyl derivative 62 was first prepared in 
1914,44 using pinacolone (74; Scheme 4) as the starting material. Under alkaline conditions, 
permanganate oxidation yields trimethylpyruvic acid 75. Condensation of the acid with 
hydroxylamine generates oxime 76 that was reduced using zinc dust/acetic acid to amino acid 62. 
Enantiospecific approaches to the same target, with higher yields, have also been more recently 
developed.45 
 





Unfortunately, despite this significant synthetic effort, a peptide comprising mostly natural 
amino acids (except for 24 in p1) showed the best binding to all DR4 alleles; however, this peptide 
was also highly susceptible to proteolysis. Inhibition studies showed that several of the synthetic 
APLs proved to be good antagonists, despite their lower affinity, when tested in conjunction with  
immunogenic peptides; but, 50% inhibition required a roughly 20:1 ratio of HLAB to natural 
antigen. One interesting result arising from this work is the reminder that binding affinity does not 
directly translate into inhibition as other factors, such as cellular uptake and degradation resistance, 
contribute greatly to immunological outcomes. Consequently, peptides with lower binding 
affinities may prove to be much better overall antagonists should they be more stable.  
 
In a similar study which continued the work, dipeptide mimetics (63, 64, 77-85) and 
glycoconjugates were incorporated into the design of a cathepsin (a peptidase) resistant, high 
affinity HLA-DR binder.46 The same preferred sequence motif described above was used as the 
baseline starting point for this study. An investigation into the importance of the peptide length 
revealed that as the peptide was truncated, affinity decreased. However, one tetrapeptide (Ac-
(Cyclohexylalanine)RMM-NH2, binding p1-p4) maintained a moderate binding affinity. This 
peptide was then extended by integrating a variety of non-amino acid compounds, such as sugars 
(i.e., Mannosamine) that can form interactions with the pockets of the HLA in place of the deleted 
amino acid residues.  In the best cases, similar binding affinities to the parent peptide were 
obtained. Dipeptide mimetics (63, 77-85) were incorporated in positions 2-3, 4-5, and 6-7 where 
peptide-receptor H-bonds form critical interactions; reducing the freedom of movement may 
improve binding. However, all of these dipeptide replacements result in lowering the affinity to 
the receptor due to unfavourable steric interactions, but all result in significantly improved 
peptidase stability and showed higher levels of T-cell inhibition. These studies highlight the 
complexity and non-trivial nature of the design of potential APLs.  
Within the series, 7,6 bicyclic pyridizine, 9-aminooctahydro-6,10-dioxo-6H- pyridazino- 
[1,2-a][1,2]diazepine-1-carboxylic acid (64 Figure 6) and a 5-amino-1,2,4,5,6,7-
hexahydroazepino[3,2,1-hi]indol-4- one-2-carboxylic acid (63 Figure 3) were found to be 
acceptable substitutes that maintain the required backbone H-bonds interactions at p2 or p4.  
Compound 64 was synthesized via N-acylation of the t-butyl ester of piperazic acid (87; 
Scheme 5)  with a glutamic acid derivative 86 to provide pseudodipeptide 88.47 Hydrogenolysis 
followed by an intramolecular N-acylation provides the seven-membered ring. Deprotection of the 
maleimide unmasks the amine 90 and a final cleavage of the t-butyl ester provides the building 




Scheme 5. Synthesis of 7,6 bicyclic pyridizine, 9-aminooctahydro-6,10-dioxo-6H- pyridazino- 
[1,2-a][1,2]diazepine-1-carboxylic acid 64.47 
 
An alternative class of dipeptides, exemplified by benzo-fused azepinone 63 were prepared 
through an intramolecular annulation.48 Indoline (92; Scheme 6) is acylated with the acid fluoride 
derivative of protected aspartic acid residue 91 to obtain ester 93. Hydrogenolysis leads to the 
formation of acid 94, which is selectively reduced and converted to the diethyl acetal 95 over three 
steps (thioester synthesis, Fukuyama reduction and conversion of the aldehyde to the acetal) to set 
up the key cycloannulation. Reaction of the acetal with polyphosphoric acid (PPA) generates 
unsaturated azepinone 96. Hydrogenation and subsequent removal of the phthalimido group leads 
to the formation of the required 7,5-fused azepinone 63. 
 
 
Scheme 6. Synthesis of benzo-fused azepinone 63.48 
As an alternative to this approach, and to increase peptidase resistance, Andersson and 
coworkers introduced oxazoles (97-99; Figure 6) into the protein backbone, replacing vulnerable 
amide bonds in the CII259-273 peptide and formed oxazole-glycoprotein peptides (example glyco-
functionalized amino acid 100).49 These peptides had low binding affinity for mouse Aq but did 
bind DR4 (there is a difference in the alignment of the pockets). However, the DR4 binding 
peptides also elicited strong T cell response. The reasoning behind the low affinities is unclear but 
it may be due to the rigidity of the oxazolone moieties. To further increase stability of the 
previously synthesized APLs43 to plasma proteins in addition to the cathepsins, Rosloniec and 
coworkers incorporated both oxazolones and other unnatural amino acids into previously tested 
APLs (101-103, Figure 7).50 Arginine in p2 was replaced with 101 to prevent its recognition by 
tryptic peptidases and the Met resdiue was replaced with norleucine to inhibit T-cell recognition. 
These peptides maintained their high affinity for DR4 and could inhibit T-cell activation in a dose 
dependent manner and were found to be effective treatments in mouse models for RA. Residue 
102 was incorporated because of its high hydrophobicity, which should allow for easier crossing 
of membranes and improve peptide uptake. The new peptides maintained their high binding 
affinity as well as their ability to inhibit T cell responses. The synthetic procedure for making 
compound 102 is interesting as it involves a de novo synthesis of an amino acids (Scheme 7).51 
Acylaminomalonate (104) is condensed with cinnamaldehyde (103) under basic conditions to form 
a phenylproline analogue, 105. Silane-mediated deoxygenation provides the pyrrolidine 106, and 
following monosaponification, the unmasked acid is lost through decarboxylation (107).  
Deprotection provides amino acid 108, that is then coupled with enantiomerically pure α-
methylbenzylamide using EDC, allowing for resolution of the two diastereomers resulting in 109. 
Rigorous cleavage of both amide bonds under forcing conditions liberates the pure amino acid 102 
that is protected as the Fmoc derivative for SPPS.  
 
 
Scheme 7. Synthesis of proline derivative 102 from achiral starting materials through a late stage 
resolution.51 
 
As mentioned, the peptides incorporating 102 also make use of achiral oxazole-based 
amino acids, and residue 99 is a typical example (Scheme 8).49 The synthesis begins with the 
deprotonation of Schiff base 110 using sodium hydride; the anion is quenched with 
phenylacetaldehyde. The imine is cleaved to provide the transient intermediate 111 that is isolated 
following coupling to glycine to generate dipeptide 112. Oxidation with Dess–Martin periodinane 
forms ketone 113, and cyclodehydration using triphenylphosphine, iodine, and triethylamine leads 
to the formation of functionalized oxazole intermediate 114. The deprotection of the Boc and t-Bu 
groups with TFA followed by N-Fmoc protection generate final product 99a, the protected 
analogue of 99. The other members of this rotationally restricted and enzymatically-stabilized class 




Scheme 8. Synthesis of Fmoc-protected oxazole derived amino acid 99.49  
 
In stark contrast to the achiral 99 is carbohydrate amino acid 100. Glycoconjugates are 
common building blocks for glycoproteins, but using one as a multivalent hydrogen-bond 
donor/acceptor is a creative solution, and the connectivity is highly unusual for an O-linked 
glycoside. The synthesis (Scheme 9)52 begins with the commercially available natural (2S,5R)-
(+)-hydroxylysine dihydrochloride salt 115 being protected as the bis-Boc derivative using 
aqueous NaHCO3 and (Boc)2O. The acid is then chemoselectively protected with ethereal-
diazomethane to obtain the (2S,SR)-(+)-ester 116. A Helferich Koenigs-Knorr glycosylation 
provides the O-glycoside 117.  Alkaline hydrolysis, and final Boc deprotection results in formation 




Scheme 9. The reported synthetic strategy for glycoconjugate 100.52  
 
 
The above reports all focused on the collagen type II epitope, but other antigens associated 
with DR4 are also potential immunodominant sequences that can act as potential starting points 
for designing new therapeutics. Boots and coworkers focused on the generation of APLs using the 
gp39263-275 epitope as the parent compound.53 The examples of unnatural amino acids used in APLs 
for the treatment of Rheumatoid Arthritis reported by Boots and coworkers (118-125) are provided 
in Figure 6. 
  
 
Figure 6. Unnatural amino acids utilized in APLs for the treatment of Rheumatoid Arthritis. 
 
Based on their investigations, they determined that Phe265 (p1) is the dominant HLA 
anchoring residue and that Ala268, Ser269, Glu271 and Thr272 (p4, p5, p7 and p8) are the core 
TCR contact residues. They then substituted p1 with a series of unnatural amino acids to attempt 
to improve affinity (118-125; Figure 6). They chose to modify the HLA contact residues because 
modifications of TCR contact residues could result in undesired immune response as was the case 
in clinical trials where patients developed allergic reactions to other APL formulations. This is a 
challenge for autoimmune peptide therapies: APLs can often induce dangerous allergic or adverse 
reactions in some individuals, leading to the termination of several clinical trials.54 Modification 
of the anchor residues can also result in a change in the structure or positioning of the protein, and 
this too can lead to altered T-cell responses despite the homology to the parent epitope.  
The APLs generated by Boots had similar binding affinities for DR4 as the original 
peptides demonstrating the flexibility of the pocket to accept alternatives to a simple phenyl ring. 
Of the substitutions tested, only two were found to be partial activators of T cells (compounds 121 
and 125). Many of the amino acids have relatively simple preparations, but 121 is a challenging 
target.55 Optically active glycinamide (126; Scheme 10) is condensed with substituted 
benzaldehyde 127 to produce, in the presence of an acid catalyst, a mixture of diastereomers (128). 
These could be readily separated through fractional crystallization to isolate the desired optically 
active imidazolidinone 129. Boc protection removes the remaining acidic proton to give precursor 
130. Deprotonation creates the enol that is then treated with benzhydryl chloride (131) installs the 
required functionality in 132. A series of deprotections: Boc and imidazolidinone hydrolysis, 
cleavage of the primary amide, and reduction of the remaining methyl benzyl group, provides the 
final amino acid 125.55 
 
Scheme 10. Synthesis of diphenyl substituted amino acid 125.55 
 
However, incorporating this diphenyl substituted amino acid 121 reduced IFN-y 
production while 125 increased cytokine production. The exact mechanism for decreased cytokine 
production is uncertain. While an interesting approach, this strategy did not result in antagonism 
or prevention of disease progression.  
 
Finally, although not a synthetic amino acid in the same class as those described above, 
citrullination plays a key role in RA pathogenesis. It can occur because of enzymatic 
transformation of arginine 133 to citrulline 134 by peptidyl arginine deiminases (PAD) (Scheme 
11). It was observed that autoantibodies in the sera of RA patients are capable of recognizing 
citrullinated peptides which are present in the synovium.56 Citrullinated peptides however were 
not used as a potential therapy but rather as a diagnostic tool. Cyclization of these peptides (which 
are recognized by autoantibodies) increased affinity to the antibodies, and thus were used to detect 
their presence in the sera of RA patients more efficiently.57 It was also noted that the collagen II 
epitopes can undergo other modifications as well, such as glycosylation, which are also recognized 
by T cells indicating a more complex mechanism.58 Citrulline introduction may prove a good 
starting point for designing the next generation of unnatural amino acids for the treatment of RA. 
 
 
Scheme 11. Conversion of peptidyl-arginine to citrulline by the PAD enzyme.  
 
Multiple Sclerosis 
Multiple sclerosis is an inflammatory disorder of the central nervous system in which 
demyelination of axons occurs along with plaque formation.59 This causes a range of neurological 
symptoms such as pain, ataxia, motor deficit, visual impairment.60 
MS has a very strong genetic association with HLA class II genes DR15 and DQw6, which 
increase susceptibility of individuals.61 Myelin basic protein (MBP), proteolipid protein and 
myelin oligodendrocyte glycoprotein are all suspected MS autoantigens; however, MBP appears 
the most responsible, and is recognized by the majority of  MS patient-derived T-cell lines. The 
most antigenic sequence appears to be MPB84-103 which contains the immunodominant epitope 
MPB83-99.62 Crystallization of the HLA-MBP-TCR ternary complex (Figure 7; PDB: 1YMM) 
reveals key structural aspects of the interactions. The TCR sits off-center over the p2 and p3 
positions which contain His and Phe residues respectively.63 These form the major contact points 
with the TCRα and TCRβ chains. Lys in P5 makes smaller contributions to TCR binding. 
Modifications of the p2 and p3 residues greatly impacted binding and modification of p5 affected 
binding to a lesser degree.64 Additionally p4 appears important for determining T-cell activation 
as the T-cell receptor interacts directly with the peptide backbone making this position relatively 
insensitive to substitution if T-cell activation is to be maintained.  
Another crystal structure of the HLA obtained by Smith and coworkers, complexed with 
MBP83-97, showed that Val87 and Phe90 (p1 and p4) were the major HLA anchor residues, with 
Asn92, Ile93 and Thr95 (p6, p7 and p9 respectively) also playing a supporting role (Crystal 
structures (1FV1); Figure 7).65 In this structure, the side chains of His88, Phe89 and Lys91 in p2, 
p3 and p5 were oriented away from the pocket which is consistent with the understanding that they 
act as TCR contact residues.65a These sites can be modified to alter the binding of APLs with either 
the HLA or the TCR.66 It was noted however that mutations in the peptide sequence of MBP87-99 
in which Lys91 is mutated to either Arg or Ala and Pro96 is mutated to Ala (generating [Arg91, 
Ala96] and [Ala91, Ala96] peptides) resulted in antagonistic peptides even though Lys91 has 
minimal contributions to binding, and Pro96 is not a TCR contact residue.67 These modifications 
can clearly have an impact on the behavior of the adjacent residues. A study by Mantzourani and 
coworkers showed that these modifications resulted in a change in peptide conformation: the 
essential TCR anchors at p2 and p3 becoming buried into the peptide groove.68 This acts as an 
additional reminder about the complexity of these systems, and emphasizes again the necessity to 
consider the emergent conformational changes that arise from any substitution. 
 
 
Figure 7. Crystal structures (1FV1)69 and the electrostatic surface map of the HLA-DR15 binding 
pocket with the antigen MBP83-97 highlighted in green. A) Overall view of the peptide-HLA 
interaction. B) View of the T-cell receptor-antigen-HLA ternary complex. The key TCR-
interacting residues, His88, Phe89 and Lys91 are highlighted in yellow. The surface of the TCR is 
provided as a translucent grey model, and the HLA is represented by the ribbons. The surface has 
been removed for clarity. C) Expanded view of the very large p4 pocket partially occupied by a 
phenylalanine. D) Edge-on view of the peptide showing the interaction between the threonine and 
the P9 pocket and end of the binding groove. MBP bends away from the groove and into the solvent 
at this C-terminus. 
 
In a study conducted by Trager and coworkers, APL peptides were modified with aza-
peptide linkages in which a carbon in the backbone is replaced by a nitrogen in an attempt to 
increase protease resistance.70 The APL they chose to modify had undergone clinical trials and 
patients developed an allergic reaction to the peptide.71 It was hypothesized that this was caused 
by use of large doses which were required due to the low bioavailability and stability of the 
peptide.71 This peptide sequence contains TCR contacts in p3 (Gln) and p6 (Pro) and HLA contacts 
in p4 (Ser) p6(Lys) and p9 (Ser), with aza-glycine being introduced at or near TCR contact points. 
Incorporation of aza-gly in p3, along with p4 substitutions to Tyr to increase HLA binding, resulted 
in the most effective APL: it demonstrated a longer half-life and acted as a partial agonist. In vivo 
studies in EAE mice showed this peptide was effective in treatment of the disease. 
Cyclization of peptides offers a potential solution to the instability of linear peptides and 
is of great interest.72 Peptide cyclizations of previously tested antagonizers based on the MBP83-99 
immunodominant epitope were synthesized and tested. In one case, the mutant peptide 
[Ala91]MBP83-99 and several analogues were cyclized in a head to tail fashion.73. Ala91 was 
replaced with several other amino acids, and in some cases double mutants were generated to 
include mutation of Pro96 to Ala96. In the unmodified peptide, Val87 and Phe90 act as MHC 
anchor residues while His88, Phe89 and Lys91 are TCR contacts.74 The cyclic analogues were 
found to be good inhibitors of EAE in mice and inhibit IFN-y production. Additionally, 
conjugation with reduced mannan through a linker peptide which resulted in increased Th2 
response via production of IL-4.75 Mannan incorporation can induce either Th1 or Th2 responses 
depending on whether it is oxidized or reduced via binding to receptors on antigen presenting cells. 
In a similar study, various cyclic analogues were tested for immunogenicity using blood 
mononuclear cells obtained from MS patients.76 These analogues were also based on the MPB87-
99 epitope and contained mutations at positions 91 and 96 (Lys91 to Arg and Pro96 to Ala double 
mutant; or only Pro96 to Ala96, single mutant). Both peptides promoted a Th2 cytokine profile and 
inhibited T cell proliferation. Both were also capable of preventing the development of EAE in 
mice when co-injected with an immunogenic peptide. The cyclic peptides also showed increased 
stability to proteases compared to non-cyclized peptides. The double mutant cyclo[Ala91, Ala96] 
MBP87-99 was also conjugated to reduced mannan and further reduced the Th1 profile.75 Another 
cyclic peptide of [Phe91]MBP83-99 conjugated to mannan also prevented T cell proliferation.77 
In another study, the cyclic and linear [Ala96]MBP87-99 was citrullinated, replacing Arg91 
and Arg97 post-synthetically using isolated PAD enzyme (see Scheme 11 above).78 Citrullination 
has been implicated in other MHC type II autoimmune disorders such as RA as described above: 
citrullinated peptides appear to be generally highly antigenic.79 As such peptide modifications are 
common, and even more so in MS patients where the majority of MPB is citrullinated, 
understanding the mechanism and effects on disease progression is desirable. The citrullinated 
peptides induced a Th1 response confirming that this modification is indeed immunogenic, and 
modification of antagonist peptides leads to inflammatory response. In both peptides, citrullinated 
residues point towards the TCR indicating that their recognition may be responsible for T cell 
activation rather than for improving binding to the HLA. The cyclic and linear citrullinated 
peptides were also conjugated to reduced mannan using a KLH carrier.80 The cyclic-KLH-mannan 
complex induced a very strong T-cell proliferation response and enhanced cytokine IFN-γ and IL-
4 production. The linear peptide, on the other hand, did not stimulate either T-cell proliferation or 
IFN-γ production. Molecular dynamics simulations of the cyclic peptide revealed that it prefers to 
sit in the middle of the binding pocket with F90 and N92 of the cyclic peptide occupying anchor 
positions p4 and p6, while p1 and p9 remain empty presumably due to strain induced by the 
macrocycle. In contrast, the citrullinated-linear-mannan peptide showed a similar conformation to 
the unmodified peptide. Differences in their T-cell activation profile can thus be attributed to the 
structural differences of the two peptides. Several studies have also focused on the use APLs based 
on myelin oligodendrocyte glycoprotein, another antigenic peptide implicated in MS disease 
progression.81 In one study, the immunogenic MOG35-55 peptide was cyclized in a head to tail 
fashion.82 This peptide was shown to reduce symptoms and severity of EAE. Computational 
modeling illustrated that this peptide binds HLA-DR2 with decreased affinity. Cyclization then 
results in different TCR contact points which the authors believe may result in TCR antagonism. 
Another study utilized MOG35-55 mutants in which TCR contact residues Arg41 and Arg46 were 
mutated with Ala to generate single or double mutants.83 These were compared to cyclic analogues 
generated by mutating those Arg residues to Lysine and cyclized to Lys55 (terminal lysine) 
through a side chain. While both were found to suppress EAE, the linear peptides had a stronger 
effect and cyclic peptides less so.  
Another method utilized of increased stability is incorporation of β-amino acids, which 
was applied to prepare altered peptide ligands based on the MOG35-55 peptide.84 In this study, 
residue 44F, a TCR contact residue, was replaced with either β-A or β-F. The resulting peptides 
had increased half-lives, potentially due to the removal of a peptidase recognition site within the 
core region of the peptide. Not, only that, but the peptide was found to suppress EAE, even when 
administered orally. This small change had a profound impact on the function of the immunogenic 
peptide. Adding the additional atom in the peptide backbone slightly shifts the entire register of 
the system, and so again has significant distal effects on the interaction between receptor and 
peptide. β amino acids substitutions85 may prove to offer a simple solution of introducing unusual 
spacing and functionality as they can both increase protease resistance and potentially introduce 
the desired antagonistic properties. 
The effects of Thiopalmitoylation on peptide ligands in MS have also been examined.86 
Thiopalmitoylation is the attachment of palmitic acid to cysteine residues via a thioester bond.87 
Myelin proteolipid protein (PLP) is abundant in the central nervous system, is often acylated, and 
has been found to be immunogenic in some MS patients.88 Thiopalmitoylation of PLP104-117 and 
PLP139-151, the immunogenic epitopes, was shown to increase immunogenicity of the peptides.89 
The linkage was also found to be important as amide linkage at the N terminus of the peptides to 
palmitic acid did not result in immunogenic peptides.89 A follow-up study to determine the 
mechanism for increased immunogenicity determined that lipopeptides are absorbed more 
efficiently in antigen presenting cells.90 Cloake and coworkers then modified PLP APLs which 
were shown to ameliorate EAE disease progression by promoting the uptake and preferential 
presentation of the modified peptides.91 These studies show that the consideration of post 
translational modifications of the peptides is important. Finally, in addition to modifying contact 
residues, modifications which affect uptake and promotion should also be considered. 
MS is potentially the most promising target of APL and HLAB intervention, and 
consequently it is a surprise that so little research has been conducted into the use of unnatural 
amino acids in this disease compared with RA and CD. The solutions from those two diseases 
should transfer well to this system. 
 
Final thoughts 
 One final example, while not strictly for an autoimmune disease, deserves mention in this 
work. All of the examples described above involve some form of design, whether it be chemical 
intuition, or some level of computer-assisted design. However, in example after example, the 
unintended emergent effects induced on surrounding residues has often had a larger impact on 
binding efficiency or T-cell blocking or modulation than the changed residue. Without a doubt, 
designed peptides will provide the greatest potential for success in delivering clinically useful 
APLs or HLABs, but the design problems are significant. The peptides are large, and the receptors 
are enormous. Solvation and entropic factors must be considered, and these are computationally 
very intensive and so limit throughput. In a very interesting study Ovaa, Rodenko and co-workers 
investigated the binding affinity of a consensus antigen for HLA-A2,92 a receptor that could be 
exploited for the development of new anti-viral vaccine formulations. Instead of the careful 
deliberation, a massively parallel library of epitopes incorporating unnatural amino acids at 
random positions, of which those provided as Figure 8 are simply a few examples, was prepared. 
Surprisingly, a large number of the generated epitopes showed considerably higher affinity for the 
receptor than the consensus sequence. In some cases, this improvement in affinity was by two 
orders of magnitude. These are generally far simpler residues than those described above. Small 
alkylated systems (60,62,135-140), or residues with the incorporation of simple π-systems 
(120,122,141-145), or slight modification of the natural residues (1, 146-149). If randomly 
substituting these residues into a peptide can lead to a two-order of magnitude improvement in 
binding affinity, rational design of unnatural amino acids could very well lead to the many orders 
of magnitude improvement in binding required for the development of clinically-relevant HLABs. 
 
 
Figure 8. Most effective unnatural amino acids used by Hoppes and co-workers in their 
investigation into random substitution of residues into HLA-binding epitopes. 
 
Conclusion 
HLA-specific therapy promises specific targeted treatment options for these and other 
autoimmune disorders using APLs and HLABs. These ligands bind to the HLA receptor and 
through either differential T cell recognition/activation or blocking are able to reduce or even in 
some cases inhibit these diseases; however, there are three major requirements for these drugs: 
efficient HLA binding, T-cell blocking or response modulation and protease resistance. 
Unfortunately, restricting options to the canonical 20 amino acids has failed to properly balance 
these three requirements. Although the incorporation of unnatural amino acids and using other 
peptide modification strategies, including cyclization and dimerization has provided encouraging 
preliminary results in providing high binding affinity, high protease resistance, and efficient T-cell 
blocking or modulation, the resulting peptides still lack ideal behavior. The rapid increase in 
computing power and the increasing understanding of receptor-ligand interactions will allow for 
improvements in designing predictive in silico techniques to help with residue design. 
Consequently, the next generation of therapeutic candidates will involve the combination of 
innovative synthetic chemistry, advanced computational modelling, and creative peptide 
architecture. Autoimmune HLABs and APLs provide an excellent platform for carrying out 
fundamental research into peptide science while offering an ideal application for exploiting 
unnatural amino acids for a biomedical application. 
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